Ayomide Vaughan

Ayomide Vaughan

Auto-generated profile, based on publicly available information

Ayomide Vaughan

Neurosurgery Department, Surgery Interest Group of Africa, Lagos, Nigeria

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2024 in World Neurosurgery: X
Verified
Journal Article
Open access
OOOlatomiwa Olukoya
Olatomiwa Olukoya
TOTemidayo Osunronbi
Temidayo Osunronbi
DJDamilola A. Jesuyajolu
Damilola A. Jesuyajolu
BUBlossom C. Uwaga
Blossom C. Uwaga
AVAyomide Vaughan
Ayomide Vaughan
LTLewis Thorne
Lewis Thorne
Sarcopenia is associated with worsened outcomes in solid cancers. Temporalis muscle thickness (TMT) has emerged as a measure of sarcopenia. Hence, this study aims to evaluate the relationship between TMT and outcome measures in patients with malignant intra-axial neoplasms. We searched Medline, Embase, Scopus and Cochrane databases for relevant studies. Event ratios with 95% confidence intervals (CI) were analysed using the RevMan 5.4 software. Where meta-analysis was impossible, vote counting was used to determine the effect of TMT on outcomes. The GRADE framework was used to determine the certainty of the evidence. Four outcomes were reported for three conditions across 17 studies involving 4430 patients. Glioblastoma: thicker TMT was protective for overall survival (OS) (HR 0.59; 95% CI 0.46–0.76) (GRADE low), progression free survival (PFS) (HR 0.40; 95% CI 0.26–0.62) (GRADE high), and early discontinuation of treatment (OR 0.408; 95% CI 0.168–0.989) (GRADE high); no association with complications (HR 0.82; 95% CI 0.60–1.10) (GRADE low). Brain Metastases: thicker TMT was protective for OS (HR 0.73; 95% CI 0.67–0.78) (GRADE moderate); no association with PFS (GRADE low). Primary CNS Lymphoma: TMT was protective for overall survival (HR 0.34; 95% CI 0.19–0.60) (GRADE moderate) and progression free survival (HR 0.23; 95% CI 0.09–0.56) (GRADE high). TMT has significant prognostic potential in intra-axial malignant neoplasms, showing a moderate to high certainty for its association with outcomes following GRADE evaluation. This will enable shared decision making between patients and clinicians.